Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | FPR1 | P21462 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639215 | 0.81 | KMT2A (0.54) | MEN1KMT2AKDM4EATMHSD17B10 | |
| SCHEMBL991380 | 0.81 | KMT2A (0.54) | MEN1KMT2AKDM4EATMHSD17B10 | |
| Hydrochloric Acid SCHEMBL2532791 | 0.79 | KMT2A (0.55) | MEN1KMT2AKDM4EATMHSD17B10 | |
| SCHEMBL13502193 | 0.79 | MRGPRX4 (0.46) | CHRM1MEN1KMT2AGAALMNA | |
| SCHEMBL29531142 | 0.76 | HSD17B10 (0.54) | CHRM1MEN1KMT2AGAALMNA | |
| SCHEMBL3870178 | 0.76 | HSD17B10 (0.68) | CHRM1MEN1KMT2AGAALMNA | |
| SCHEMBL1678581 | 0.76 | HSD17B10 (0.54) | CHRM1MEN1KMT2AGAALMNA | |
| SCHEMBL11119661 | 0.76 | SLC6A4 (0.50) | CHRM1MEN1KMT2ALMNAMRGPRX4 | |
| SCHEMBL8979487 | 0.75 | FPR1 (0.48) | FPR1MEN1KMT2AGAALMNA | |
| SCHEMBL11118737 | 0.75 | CHRM1 (0.48) | CHRM1MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662956-B2 | Tetrahydrobenzo[d]azepin-2-one derivatives and the use thereof for treating cardiovascular diseases | BAYER SHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7662956-B2 | Tetrahydrobenzo[d]azepin-2-one derivatives and the use thereof for treating cardiovascular diseases | BAYER SHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7662956-B2 | Tetrahydrobenzo[d]azepin-2-one derivatives and the use thereof for treating cardiovascular diseases | BAYER SHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| EP-1716118-B1 | TETRAHYDROBENZO[D]AZEPIN-2- ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1716118-B1 | TETRAHYDROBENZO[D]AZEPIN-2- ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| EP-1716118-A1 | TETRAHYDROBENZO[D]AZEPIN-2- ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077907-A1 | TETRAHYDROBENZO[D]AZEPIN-2- ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | APOB, PCSK9, BDKRB1 | CHRM1 4029/4885FPR1 1742/4885MEN1 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.